Markets:

Overview

News

Currencies

International

Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.810 +0.080 (+4.62%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023 ↗

March 26, 2024

GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Gain Therapeutics: Q4 Earnings Insights ↗

March 26, 2024

Via Benzinga

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease ↗

March 05, 2024

Gain Therapeutics' GBA1 Parkinson's disease focused GT-02287's mechanism of action, tackling GCase misfolding to enhance lysosomal activity.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 16, 2024

Via Benzinga

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 21, 2023

Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the...

Via Benzinga

Expert Ratings for Gain Therapeutics ↗

June 12, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 20, 2023

Via Benzinga

These Apple Insiders Are Selling Shares of AAPL Stock ↗

October 04, 2023

Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL.

Via InvestorPlace

Why Is Nvni Group (NVNI) Stock Down 8% Today? ↗

October 04, 2023

Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger.

Via InvestorPlace

Why Is Gain Therapeutics (GANX) Stock Moving Today? ↗

October 04, 2023

Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

October 04, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday.

Via InvestorPlace

Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know ↗

May 15, 2023

Via Benzinga

Where Gain Therapeutics Stands With Analysts ↗

May 15, 2023

Via Benzinga

Analyst Expectations for Gain Therapeutics's Future ↗

May 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 ↗

September 12, 2023

Via Benzinga

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

August 29, 2023

--News Direct--

Via News Direct

Expert Ratings for Gain Therapeutics ↗

December 09, 2022

Via Benzinga

Analyst Ratings for Gain Therapeutics ↗

December 09, 2022

Via Benzinga

Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program ↗

September 26, 2022

Via Benzinga

Gain Therapeutics: Q2 Earnings Insights ↗

August 08, 2022

Gain Therapeutics (NASDAQ:GANX) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Gain Therapeutics Q1 Earnings ↗

May 16, 2022

Gain Therapeutics (NASDAQ:GANX) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67% ↗

November 25, 2022

Via Benzinga

Heska To $165? Plus BTIG Cuts PT On This Stock By 67% ↗

November 14, 2022

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...

Via Benzinga

AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday ↗

November 14, 2022

Baird raised Advanced Micro Devices, Inc. (NASDAQ: AMD) price target from $65 to $100. . Baird analyst Tristan Gerra upgraded the stock from Neutral to Outperform. AMD shares rose 5.7% to close at...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022 ↗

August 19, 2022

Upgrades

Via Benzinga

Apple To $185? Here Are 5 Other Price Target Changes For Friday ↗

August 19, 2022

Keybanc raised the price target on Apple Inc. (NASDAQ: AAPL) from $177 to $185. However, Keybanc analyst Brandon Nispel maintained the stock with an Overweight. Apple shares fell 0.9% to $172.63 in...

Via Benzinga

Gain Therapeutics: Reasons For Optimism ↗

August 09, 2022

In biotechnology, potential rules. And in Gain's case, the potential to not just treat but functionally cure at least some forms of Parkinson's Disease is strong enough to weather early-stage...

Via Talk Markets

Aggregate Insider Buying Remains Elevated For A Third Week $AMH ↗

May 23, 2022

In another challenging week for the markets where the Nasdaq dropped nearly 4%, insiders once again significantly stepped up their insider purchases for a third week in a row. We saw an increase across...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

May 10, 2022

Good morning! We're starting off another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

92 Biggest Movers From Friday ↗

May 09, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

Headline News about Gain Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today